share_log

The 38% Return This Week Takes AC Immune's (NASDAQ:ACIU) Shareholders One-year Gains to 57%

The 38% Return This Week Takes AC Immune's (NASDAQ:ACIU) Shareholders One-year Gains to 57%

本週38%的回報率使AC Immune(納斯達克股票代碼:ACIU)股東一年的漲幅達到57%
Simply Wall St ·  05/14 06:06

Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly boost your returns by picking above-average stocks. For example, the AC Immune SA (NASDAQ:ACIU) share price is up 57% in the last 1 year, clearly besting the market return of around 26% (not including dividends). So that should have shareholders smiling. In contrast, the longer term returns are negative, since the share price is 50% lower than it was three years ago.

對指數基金的被動投資可以產生與整個市場大致相匹配的回報。但是,您可以通過選擇高於平均水平的股票來顯著提高回報。例如,AC Immune SA(納斯達克股票代碼:ACIU)的股價在過去1年中上漲了57%,顯然超過了約26%(不包括股息)的市場回報率。因此,這應該讓股東們微笑。相比之下,長期回報率爲負,因爲股價比三年前低50%。

After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.

在過去一週強勁上漲之後,值得一看的是長期回報是否是由基本面改善推動的。

Given that AC Immune didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally hope to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

鑑於AC Immune在過去十二個月中沒有盈利,我們將專注於收入增長,以快速了解其業務發展。當一家公司沒有盈利時,我們通常希望看到良好的收入增長。這是因爲快速的收入增長可以很容易地推斷出來預測利潤,通常規模相當大。

AC Immune grew its revenue by 276% last year. That's stonking growth even when compared to other loss-making stocks. The solid 57% share price gain goes down pretty well, but it's not necessarily as good as you might expect given the top notch revenue growth. So quite frankly it could be a good time to investigate AC Immune in some detail. Since we evolved from monkeys, we think in linear terms by nature. So if growth goes exponential, opportunity may exist for the enlightened.

去年,AC Immune的收入增長了276%。即使與其他虧損的股票相比,這也是驚人的增長。57%的股價穩步上漲幅度不錯,但鑑於收入增長幅度最高,不一定像你預期的那麼好。因此,坦率地說,現在可能是詳細研究AC Immune的好時機。由於我們是從猴子進化而來的,所以我們天生就以線性方式思考。因此,如果增長呈指數級增長,開明者可能有機會。

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

下圖顯示了收入和收入隨時間推移的跟蹤情況(如果您點擊圖片,可以看到更多細節)。

earnings-and-revenue-growth
NasdaqGM:ACIU Earnings and Revenue Growth May 14th 2024
納斯達克通用汽車公司:ACIU 收益和收入增長 2024 年 5 月 14 日

This free interactive report on AC Immune's balance sheet strength is a great place to start, if you want to investigate the stock further.

如果你想進一步調查AC Immune的資產負債表實力,這份關於AC Immune資產負債表實力的免費互動報告是一個很好的起點。

A Different Perspective

不同的視角

We're pleased to report that AC Immune shareholders have received a total shareholder return of 57% over one year. There's no doubt those recent returns are much better than the TSR loss of 6% per year over five years. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 3 warning signs for AC Immune that you should be aware of.

我們很高興地向大家報告,AC Immune的股東在一年內獲得了57%的總股東回報率。毫無疑問,最近的回報遠好於五年內每年6%的股東總回報率損失。長期虧損使我們保持謹慎,但短期股東總回報率的增長無疑暗示着更光明的未來。儘管市場狀況可能對股價產生的不同影響值得考慮,但還有其他因素更爲重要。例如,我們已經確定了你應該注意的三種AC Immune警告信號。

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

對於那些喜歡尋找中獎投資的人來說,這份最近有內幕收購的成長型公司的免費名單可能只是門票。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論